Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL)
| Autor: | Nathalie Cambier, Guillaume Chanteau, Guillaume Escure, Remi Tilmont, Mathieu Wemeau, Jean Baptiste Bossard, Loïc Renaud, Julia Hieulle, Sarah Barbieux, Franck Morschhauser, Eileen M Boyle, Louis Terriou, Benjamin Carpentier |
|---|---|
| Přispěvatelé: | Hôpital Claude Huriez [Lille], CHU Lille, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Saint Vincent de Paul de Lille, Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL), Université catholique de Lille (UCL)-Université catholique de Lille (UCL), Centre hospitalier [Valenciennes, Nord], Memorial Sloane Kettering Cancer Center [New York], Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe Hospitalier de l'Institut Catholique de Lille (GHICL) |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty [SDV]Life Sciences [q-bio] Best Overall Response Gastroenterology Unmet needs Central Nervous System Neoplasms 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Piperidines Refractory Internal medicine Antineoplastic Combined Chemotherapy Protocols Temozolomide Humans Medicine ComputingMilieux_MISCELLANEOUS Aged Retrospective Studies Aged 80 and over business.industry Adenine Neoplasms Second Primary Hematology General Medicine Middle Aged Prognosis medicine.disease Survival Analysis Confidence interval 3. Good health Lymphoma chemistry 030220 oncology & carcinogenesis Charlson comorbidity index Ibrutinib Female Lymphoma Large B-Cell Diffuse Neoplasm Recurrence Local business 030215 immunology medicine.drug |
| Zdroj: | European Journal of Haematology European Journal of Haematology, 2021, European Journal of Haematology, 107 (3), pp.370-373. ⟨10.1111/ejh.13667⟩ |
| ISSN: | 1600-0609 0902-4441 |
| DOI: | 10.1111/ejh.13667 |
| Popis: | Despite recent therapeutic advances the outcome of elderly or frail patients with Recurrent/Refractory (R/R) Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL) is particularly dire. We retrospectively analyzed 22 immunocompetent adults with R/R PCNSL or SCNSL treated with both temozolomide and ibrutinib in five French centers, from June 2015 to January 2020. The median age at treatment initiation was 71 (range, 44 - 89 years). All patients had relapsed (n=6) or refractory (n=16) disease, after a median of two lines of therapy (range, 1-3). The median Charlson Comorbidity Index was 5 (range, 2-8). Patients received a median of 3.2 cycles (1-19 cycles). The best overall response rate was 55% (12/22) including three (13.6%) complete responses. After a median follow-up of 18.2 months (range, 5.1 - 61.7), the median progression-free survival (PFS) and overall survival (OS) were 5.3 months (95% confidence interval [CI]; 3.10 - ∞) and 8.9 months (95% CI; 5.2 - ∞) respectively. Among responders, the median PFS and OS were 11.7 months (95% CI; 7 - ∞) and 21.8 months (95% CI; 10 - ∞) respectively. Our data suggest temozolomide combined with ibrutinib displayed clinical activity with manageable side effects might be an option in these frail R/R CNS lymphomas in unmet need. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|